EP2258863A1 — miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics
Assigned to Universita degli Studi di Roma La Sapienza · Expires 2010-12-08 · 15y expired
What this patent protects
The invention refers to diagnosis and therapy of muscle degenerative disorders, as Duchcnnc Muscular Dystrophy (DMD by means of a class of specific miRNAs. In particular the invention refers to a method for the diagnosis of a muscle disorder and damage leading to muscle fiber deg…
USPTO Abstract
The invention refers to diagnosis and therapy of muscle degenerative disorders, as Duchcnnc Muscular Dystrophy (DMD by means of a class of specific miRNAs. In particular the invention refers to a method for the diagnosis of a muscle disorder and damage leading to muscle fiber degeneration, inflammation and fibrosis or for monitoring the progress of therapeutic treatments on subjects affected by said disorder consisting in detecting in a biological sample at least two of dystromiR molecules, each of the two dystromiR molecules belonging to one of the following groups: a) muscle regeneration (miR-206, miR-34), b) muscle differentiation (mix-1, miR-133), c) inflammatory (miR-223, miR-21) and d) tissue integrity (miR-29, miR-30).
Drugs covered by this patent
- Amondys 45 (CASIMERSEN) · Sarepta
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.